In:
Nature Communications, Springer Science and Business Media LLC, Vol. 6, No. 1 ( 2015-09-29)
Abstract:
The identification of small molecules that target specific CFTR variants has ushered in a new era of treatment for cystic fibrosis (CF), yet optimal, individualized treatment of CF will require identification and targeting of disease modifiers. Here we use genome-wide association analysis to identify genetic modifiers of CF lung disease, the primary cause of mortality. Meta-analysis of 6,365 CF patients identifies five loci that display significant association with variation in lung disease. Regions on chr3q29 ( MUC4/MUC20; P =3.3 × 10 −11 ), chr5p15.3 ( SLC9A3; P =6.8 × 10 −12 ), chr6p21.3 (HLA Class II ; P =1.2 × 10 −8 ) and chrXq22-q23 (AGTR2/SLC6A14; P =1.8 × 10 −9 ) contain genes of high biological relevance to CF pathophysiology. The fifth locus, on chr11p12-p13 ( EHF/APIP; P =1.9 × 10 −10 ), was previously shown to be associated with lung disease. These results provide new insights into potential targets for modulating lung disease severity in CF.
Type of Medium:
Online Resource
ISSN:
2041-1723
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2015
detail.hit.zdb_id:
2553671-0
Bookmarklink